| Date | Title | Description | |
|---|---|---|---|
| 21 Feb 2023 | On business and financial situation | The Company releases the press release related to the full year 2022 financial results. | Download |
| 21 Feb 2023 | On business and financial situation | The company releases the Integrated Report for the year 2022 | Download |
| 23 Nov 2022 | On business and financial situation | The Company releases the presentation related to its strategy update because of its 2022 Capital Markets Day | Download |
| 04 Nov 2022 | On business and financial situation | The Company releases the press release related to the first nine months of 2022 financial results | Download |
| 04 Nov 2022 | On business and financial situation | The Company releases the first nine months 2022 financial results presentation | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 29 Jun 2026 | Other relevant information | The Company informs about the dividends payment. | Download |
| 17 Jun 2026 | Announcement of general shareholders’ meeting | The Company reports on the resolutions adopted by the Ordinary General Shareholders' Meeting. | Download |
| 06 May 2026 | Announcement of general shareholders’ meeting | The Company announces the calling of its 2026 Ordinary General Shareholder´s Meeting. | Download |
| 01 Apr 2026 | On corporate transactions | ROVI announces the closing of the Asset Purchase Agreement entered into in September 2025 for the acquisition of a pharmaceutical manufacturing facility in Phoenix, Arizona (USA) | Download |
| 25 Feb 2026 | Annual Corporate Governance Report | The Company submits the Annual Corporate Governance Report for fiscal year 2025. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Feb 2019 | Información sobre resultados | ROVI releases the presentation related to the full year 2018 results | Download |
| 26 Feb 2019 | Información sobre resultados | ROVI releases the press release related to the full year 2018 results | Download |
| 15 Feb 2019 | Others on business performance and financial information | ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets | Download |
| 09 Jan 2019 | Others on business performance and financial information | ROVI informs about the adquisition of Falithrom® for the German market | Download |
| 08 Jan 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2018 | Download |